Organon: Certainly A Risky Bet, But Looks Increasingly Compelling …
17 hours ago · Organon's debt service has increased significantly since 2022 and is currently estimated to be around $520 million in 2024. Assuming free cash flow in 2024 of approximately $1 billion (excluding ...
News - Organon
Sep 18, 2024 · Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%. October 09, 2024. Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024. September 30, 2024.
Update on FDA Review of VTAMA - Business Wire
Nov 5, 2024 · JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and ...
Investors Heavily Search Organon & Co. (OGN): Here is What You …
Nov 4, 2024 · For the current quarter, Organon is expected to post earnings of $0.98 per share, indicating a change of +11.4% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.1% over the ...
Organon & Co. - Update on FDA Review of VTAMA® (tapinarof) …
Nov 5, 2024 · Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months the target action date of its review of the supplemental New Drug Application (sNDA) for VTAMA ® (tapinarof) cream, 1% as a …
OGN.N - | Stock Price & Latest News | Reuters
2 days ago · Get Organon & Co (OGN.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.
Organon Announces Proposed $1.0 Billion Senior Notes Offering
JERSEY CITY, N.J., May 07, 2024 -- (BUSINESS WIRE)--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon...
Organon Reports Results for the Fourth Quarter and Full Year …
Dec 31, 2023 · Total revenue was $6.3 billion for full year 2023, an increase of 1% as-reported and an increase of 3% ex-FX, compared with the full year 2022. Women’s Health revenue increased 2% as-reported and 3% ex-FX for full year 2023 compared with 2022.
Organon Announces New Head of Research and Development
Dec 5, 2023 · JERSEY CITY, N.J., DECEMBER 5, 2023 – Organon (NYSE: OGN) today announced that Dr. Sandra Milligan, global Head of. Research and Development, will be leaving the company on January 5, 2024. Effective January 1, 2024, Dr. Juan Camilo.
Organon & Co. (OGN) Stock Price, News, Quote & History - Yahoo Finance
Find the latest Organon & Co. (OGN) stock quote, history, news and other vital information to help you with your stock trading and investing.
- Some results have been removed